Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH
Open Access
- 1 December 2017
- journal article
- practice guideline
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 15 (12) , 2461-2465
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- What is the role for population pharmacokinetics in hemophilia?International Journal of Pharmacokinetics, 2017
- The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia AExpert Opinion on Drug Metabolism & Toxicology, 2016
- Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualizationJournal of Thrombosis and Haemostasis, 2016
- Population pharmacokinetics of recombinant factor VIII Fc fusion proteinClinical Pharmacology in Drug Development, 2014
- Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia BClinical Pharmacokinetics, 2014
- Measurement of factor VIII pharmacokinetics in routine clinical practiceJournal of Thrombosis and Haemostasis, 2012
- Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weightBlood, 2012
- Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophiliaHaemophilia, 2010
- Population pharmacokinetics of recombinant factor VIII:C (ReFacto®) in adult HIV-negative and HIV-positive haemophilia patientsEuropean Journal of Clinical Pharmacology, 2009
- Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 yearsEuropean Journal of Clinical Pharmacology, 2009